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Abstract
Cardiomyopathy is a disease of the heart muscle that can affect any age group or gender and 
can be acquired or inherited. Its literal meaning is “heart muscle disease” and refers to the 
deterioration of the function of the myocardium for any reason. Cardiomyopathy affects the 
shape, function, and/or electrical system of the heart. Patients with cardiomyopathy can pres-
ent to anaesthesiologists in emergency situations or as elective cases. The patients are usually 
not aware of their condition and may be diagnosed at the time of pre-anaesthetic check-up. 
Advanced cases are always a challenge to the anaesthesiologist as they are most commonly 
complicated by progressive cardiac failure. Patients with cardiomyopathy are often at risk 
of dysrhythmias or sudden cardiac death. This chapter describes the main features and peri-
operative management of patients with cardiomyopathies undergoing non-cardiac surgery. 
In general, the optimal anaesthetic management of patients with cardiomyopathy requires 
good preoperative assessment, close perioperative monitoring, suitable anaesthetic agents, 
optimal perioperative fluid management, and an overall stable hemodynamic status.
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1. Introduction
The first officially accepted definition of cardiomyopathy was given by WHO in 1980 which 
defined it as “heart muscle diseases of unknown cause” to differentiate cardiomyopathy from 
cardiac dysfunction which occurs due to known cardiovascular diseases such as hyperten-
sion, coronary artery disease, or valvular disease [1]. WHO reclassified cardiomyopathies in 
1995 to include diseases of myocardium associated with cardiac dysfunction that were earlier 
excluded. They expanded this criterion in order to include all known causes of cardiomyopa-
thy and is based on anatomical and physiological features. It includes three main types of 
cardiomyopathy: hypertrophic (HCM), dilated (DCM), and restrictive (RCM).
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In 2006, American Heart Association (AHA) in their document entitled “Contemporary 
Definition and Classification of the Cardiomyopathies” defined cardiomyopathies as “a het-
erogeneous group of diseases of the myocardium associated with mechanical and/or electrical 
dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or 
dilation and are due to a variety of causes that frequently are genetic. Cardiomyopathies either 
are confined to the heart or are a part of generalised systemic disorders, often leading to cardio-
vascular death or progressive heart failure-related disability.” According to the new AHA clas-
sification, cardiomyopathies are divided into two broad groups: primary cardiomyopathies and 
secondary cardiomyopathies. Primary cardiomyopathies encompass those that are exclusively 
or predominantly confined to the heart muscle and are acquired, genetic, or of mixed origin. 
Secondary cardiomyopathies include the subset of multiorgan involving diseases, which cause 
involvement of the heart as a part of their pathophysiology. In spite of this detailed classification, 
some confusion may arise because some primary cardiomyopathies may have associated extra 
cardiac components while as a few secondary cardiomyopathies can affect the heart exclusively.
Classification of primary cardiomyopathies:
Classification of secondary cardiomyopathies:
Genetic Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy
Left ventricular noncompaction
Glycogen storage disease
Conduction system disease (Lenègre’s disease)
Ion channelopathies: long QT syndrome, Brugada syndrome, short QT syndrome
Mixed Dilated cardiomyopathy
Primary restrictive nonhypertrophied cardiomyopathy
Acquired Myocarditis (inflammatory cardiomyopathy): viral, bacterial, rickettsial, fungal, parasitic (Chagas 
disease)
Stress cardiomyopathy
Peripartum cardiomyopathy
Infiltrative Amyloidosis
Gaucher’s disease
Hunter’s syndrome
Storage Hemochromatosis
Glycogen storage disease
Niemann-Pick disease
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European Society of Cardiology in 2008 introduced a classification in which they accommo-
dated five specific types of cardiomyopathies along with their genetic involvement: dilated, 
hypertrophic, arrhythmogenic, restrictive, and unclassified [2]. They further divided them 
into familial (genetic) or non-familial (non-genetic).
The most recent classification known as the MOGE(S) classification system had been intro-
duced which is based on phenotype and genotype an it incorporates information on struc-
tural and functional abnormalities (M), organ involvement (O), genetics (G), aetiology (E), 
and disease severity (S) associated with the condition [3]. However, it cannot be considered as 
complete as it does not include certain cardiomyopathies like postpartum cardiomyopathy or 
the risk of sudden death and is very complex to use. The MOGES classification is beyond the 
scope of this review so we do not discuss it here.
2. Pathophysiology
Cardiomyopathy itself can present as either systolic dysfunction or diastolic dysfunction, 
which in turn are both related to the ventricular dysfunction.
Toxic Drugs: cocaine, alcohol
Chemotherapy drugs: doxorubicin, daunorubicin, cyclophosphamide
Heavy metals: lead, mercury
Radiation therapy
Inflammatory Sarcoidosis
Endomyocardial Hypereosinophilic (Löffler’s) syndrome
Endomyocardial fibrosis
Endocrine Diabetes mellitus
Hyper- or hypothyroidism
Pheochromocytoma
Acromegaly
Neuromuscular Duchenne-Becker dystrophy
Neurofibromatosis
Tuberous sclerosis
Autoimmune Lupus erythematosus
Rheumatoid arthritis
Scleroderma
Dermatomyositis
Polyarteritis nodosa
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Systolic dysfunction: This type of dysfunction is mainly seen in dilated cardiomyopathy. 
The predominant pathophysiology is a global decrease in myocardial contractility, which in 
turn leads to reduction in left ventricular ejection fraction. In the initial phases, the heart tries 
to compensate this change by increasing the size of left ventricular cavity which allows for 
an improvement in stroke volume with an associated improved force of contraction. As the 
disease progresses, these compensatory mechanisms prove to be inadequate in maintaining 
the cardiac output, eventually leading to the failure of left heart.
Diastolic dysfunction: This is the most common type of dysfunction associated with the car-
diomyopathies, occurring in HCM, RCM, and other types of cardiomyopathies. The main 
pathophysiology is impairment of filling of blood in the left ventricle, which leads to increase 
in the left ventricular filling pressures. During the beginning of the diastolic phase of a normal 
cardiac cycle, left ventricle undergoes the phase of Isometric relaxation (which is an energy 
dependent process) just before the start of left ventricle filling phase. This relaxation continues 
in the early left ventricular filling phase. The later part of the left ventricular filling is a pas-
sive process and depends on the compliance of the left ventricle. Diastolic dysfunction can 
be because of the impairment of any of the two phases: active relaxation or left ventricular 
compliance or a combination of the two. Ischaemia mainly affects the phase of isometric relax-
ation, while intrinsic myocardial pathologies including fibrosis or external restriction due to 
pericardial diseases may lead to a reduction in left ventricular compliance.
The main types of cardiomyopathy that we come across clinically in our day-to-day practice 
are:
• Dilated cardiomyopathy
• Hypertrophic cardiomyopathy
• Restrictive cardiomyopathy
• Arrhythmogenic right ventricular dysplasia
• Peripartum cardiomyopathy
Some other types of cardiomyopathy are known as “unclassified cardiomyopathy.” Another 
type of cardiomyopathy known as Takotsubo cardiomyopathy has been recently listed and is 
also known as “stress-induced cardiomyopathy,” or broken heart syndrome.
Therefore, we focus our attention towards the commonest types of cardiomyopathies in this 
chapter.
3. Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is defined by cardiac enlargement with impaired systolic 
function of one or both ventricles. It is defined by the presence of:
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a. Fractional myocardial shortening <25% and/or ejection fraction <45%.
b. Left ventricular end-diastolic diameter > 117% excluding any known cause of myocardial 
disease.
Familial DCM contribute about 20–48% of all DCM and can defined by
• the presence of two or more affected relatives with DCM meeting the above criteria or
• a relative of a DCM patient with unexplained sudden death before the age of 35.
The prevalence of DCM is 920/100,000 individuals and is common in Afro-Caribbean popu-
lation. It is the commonest form of cardiomyopathy and is the third most common cause 
of congestive heart failure. DCM is the commonest indication for heart transplantation. In 
30–40% patients, it is transmitted in an autosomal dominant fashion while in others it can be 
post viral or idiopathic. It can be of ischemic or nonischemic variety with ischemic type being 
related to atherosclerosis or CAD. The nonischemic variety may present itself secondary to 
the use of chemotherapeutic agents (doxorubicin and adriamycin), infections (Coxsackie 
virus, HIV, cytomegalovirus Chagas’ disease, trichinosis, toxoplasmosis, Lyme disease, and 
leptospirosis), drug abuse (alcohol, heroin, cocaine, and methamphetamines), or as peripar-
tum cardiomyopathy.
3.1. Pathophysiology
Dilated cardiomyopathy presents with a decrease in LV ejection fraction (LVEF) as described 
earlier, congestive heart failure (CHF) or as ventricular arrhythmias. Initially, the ventricle 
dilates to increase the force of contraction and stroke volume in order to maintain the cardiac 
output (Frank-Starling law); however, as the disease progresses, these compensatory mecha-
nisms gradually fail, leading to the ventricular failure and ultimately failure to maintain the 
cardiac output (CO).
3.2. Signs and symptoms
The patients of dilated cardiomyopathy present with symptoms like dyspnea, orthopnea, 
fatigue, weakness, and oedema in the lower extremities. Physical findings are similar to 
those seen in CHF. Some patients complain of dyspnea on exertion that may look like 
angina pectoris. Patients may have jugular venous distention, crepitation on auscultation, 
resting tachycardia, audible s3 and s4 heart sounds, pulmonary oedema, and cardiomegaly. 
Mitral and/or tricuspid regurgitation may be audible clinically if the ventricular dilation is 
marked.
The ECG may show ST-T segment abnormalities, atrial fibrillation, intraventricular conduc-
tion defects, and PVCs. The echocardiography reveals dilated cardiac chambers, global hypo-
kinesia, low EF/fractional shortening, raised LVEDP, mitral or tricuspid regurgitation and/or 
mural thrombi. Right-sided cardiac catheterisation using a Swan Ganz Catheter reveals a high 
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pulmonary capillary wedge pressure, high systemic vascular resistance, and a low cardiac 
output. Additional laboratory tests carried out may reveal raised brain natriuretic peptide 
levels.
3.3. Treatment
Management of DCM begins with lifestyle modifications such as adequate rest, weight con-
trol, low sodium diet, fluid restriction, stopping alcohol intake and smoking, and less physical 
activity during periods of cardiac decompensation.
Medical management: The patients of DCM are at increased risk of pulmonary and systemic 
thromboembolisation due to stasis of blood in the dilated hypokinetic cardiac chambers. 
Anticoagulation therapy with warfarin or dabigatran is often indicated in these patients. The 
risk of embolisation is the highest in patients with atrial fibrillation, severe left ventricular dys-
function, a previous history of thromboembolism, or echocardiographic evidence of a mural 
thrombus. Other medications like angiotensin-converting enzyme inhibitors and angiotensin 
antagonists, diuretics, beta blockers, vasodilators, digoxin, antiarrhythmics, and statins can 
be prescribed to keep the condition under control.
Patients with a LVEF <30% and an intraventricular conduction defect with wide QRS complex 
≥130 ms may lack synchronised contraction of both ventricles. Resynchronisation of right 
and left ventricle with biventricular pacing using a cardiac resynchronisation therapy device 
(CRT-D) can restore synchronous contraction of both ventricles, shorten the QRS interval, 
decrease left ventricular size and improve systolic function, stroke volume and the overall 
survival rate of patients.
Heart transplantation is the definitive treatment and the most common indication for trans-
plantation in patients with DCM for both adults and children. Patients that are likely to benefit 
highly from a heart transplant include patients who were previously very active, <60 years 
of age who show intractable symptoms of congestive heart failure despite optimal medical 
therapy.
3.4. Prognosis
Symptomatic patients with DCM who are referred to tertiary medical centres for care have 
a high 5-year mortality rate (50%). If the cardiomyopathy involves both the right and left 
ventricles, the prognosis is very poor. Haemodynamic abnormalities that predict a poor prog-
nosis include:
• an ejection fraction <25%,
• pulmonary capillary wedge pressure > 20 mm Hg,
• cardiac index <2.5 L/min/m2,
• pulmonary hypertension,
• systemic hypotension, and
• an increased central venous pressure.
Current Topics in Intensive Care Medicine110
3.5. Anaesthetic management for non-cardiac surgery
Any major surgeries on these patients can be associated with morbidity and mortality, there-
fore, requires planning. Optimisation of congestive heart failure (CHF) at least for a week 
before the planned surgery is advisable. In critically ill or patients undergoing a high-risk 
procedure or those in which CHF is not appropriately managed, intra-arterial BP line should 
be inserted preoperatively. Premedication should be tailored according to the patient’s 
requirement and may include short acting anxiolytic and/or sedative. Regional anaesthesia 
or nerve blocks alone or in combination with general anaesthesia can help us achieve the 
set goals of anaesthesia with a minimal haemodynamic compromise. However, the ongo-
ing anticoagulation therapy may limit the option of regional anaesthesia. American Society 
of Regional Anaesthesia (ASRA) guidelines must be strictly followed if the patient is on an 
anticoagulation therapy.
The goals of anaesthesia are to [4]:
• minimise any negative inotropic effect of anaesthetic drugs.
• prevent increases in afterload.
• maintain preload despite increased left ventricular end-diastolic pressure.
• maintain perfusion and control arrhythmias,
• avoid hypotension and tachycardia.
• avoid overdose of medications during induction as the circulation time of drugs is slow.
These patients can become haemodynamically unstable due to the depressant effect of anaes-
thetic agents, fluid shifts and ongoing blood loss, which add to the already poor myocar-
dial function due the cardiomyopathy. Propofol, thiopentone and inhalational agents cause 
vasodilation and myocardial depression. Benzodiazepines like midazolam and nitrous oxide 
may cause cardiovascular depression. Etomidate, ketamine, and narcotics like opioids are 
the ones that have minimal adverse haemodynamic response. We need to use a balanced 
anaesthetic technique. Slow induction should be carried out. Response of induction agents 
may be delayed due to prolonged circulation time, so slow and titrated doses of anaesthetic 
agents should be administered. Additional doses may not be required.
Optimal pain management helps to maintain haemodynamic stability. Regional anaesthesia 
may be a source of excellent postoperative pain relief, reducing the episodes of sympatheti-
cally mediated tachycardia, and afterload increases.
Monitoring: In addition to basic monitoring, central venous pressure (CVP) monitoring allows 
us to measure preload and central venous saturation (ScVO
2
). It provides for an access to 
administer inotropes and vasoconstrictors if needed. Direct intra-arterial pressure monitor-
ing enables early identification of haemodynamic alterations by beat-to-beat measurement 
of BP. Pulmonary artery pressure monitoring is useful in patients undergoing high-risk or 
emergency surgery or those in whom large fluid shifts are anticipated. The role of noninvasive 
methods to estimate cardiac output as well as estimate global end-diastolic volumes, the extra-
vascular lung water, and other indices if available are invaluable for assessing cardiac function.
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Transesophageal echocardiography (TEE) is also helpful as it identifies causes of hypoten-
sion, response to fluid therapy or inotrope support, estimates preload, cardiac output, dia-
stolic dysfunction, valve function, and regional wall motion abnormalities.
4. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy can be defined as abnormal LV thickening without chamber 
dilation that is usually asymmetrical, develops in the absence of an identifiable cause (e.g. aor-
tic valvular stenosis[AS] and hypertension), and is associated with myocardial fibre disarray.
Hypertrophic cardiomyopathy (HCM) is very common and can affect people of any age 
group. It affects both sexes equally. It is a cause of sudden cardiac arrest and death in appar-
ently healthy young people, including young athletes. HCM is a relatively common inherited 
disorder with an autosomal dominant pattern of inheritance with variable expression and has 
a prevalence of 1 in 500.
Defects of at least 11 genes and >1440 mutations sites demonstrate its genomic heterogeneity.
4.1. Pathophysiology
The underlying structural abnormalities in HCM are:
1. myocardial cell disarray where the cells are rearranged in a disorganised pattern as 
opposed to a normal parallel myocyte arrangement;
2. coronary microvasculature dysfunction due to increased wall to lumen ratio; and.
3. remodelling changes occurring in the heart.
These changes in HCM patients lead to diastolic dysfunction, impaired coronary reserve, 
supraventricular and ventricular dysrhythmias, and sudden cardiac arrest. Left ventricular 
remodelling can include fibrosis, focal, diffuse, asymmetric, or concentric hypertrophy, as 
well as decrease in the cavity size. The most common subtype of HCM presents as hypertro-
phy of the septum and the anterio-lateral free wall.
LV outflow tract obstruction (LVOTO) occurs in HCM, and initially it was proposed that 
the basal septal hypertrophy encroaching on the LVOT caused the obstruction of the tract. 
However, more recent studies have pointed towards the fact that during ventricular systole, 
flow against an abnormally positioned mitral valvular apparatus results in a Venturi effect on 
the anterior leaflet of the mitral valve and induces systolic anterior movement (SAM) of the 
anterior mitral valve leaflet. The mitral valve apparatus abnormalities can include hypertro-
phied papillary muscles touching the septum, elongated mitral leaflets, anterior displacement 
of papillary muscles, or anomalous insertion of the papillary muscle onto the anterior mitral 
leaflet. LVOTO can be precipitated or aggravated by increased contractility of the heart or 
tachycardia or decreased end-diastolic volume or systemic vascular (arterial) resistance. With 
HCM, incidence of diastolic dysfunction is more than LVOTO.
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Myocardial ischaemia is present in patients with HCM, irrespective of the presence or absence 
of coronary artery disease. Myocardial ischaemia is precipitated by several factors including
• a mismatch between ventricular mass and coronary artery size,
• increased oxygen consumption due to hypertrophy,
• abnormal coronary arteries,
• decreased diastolic filling time,
• increased LVEDP compromising coronary perfusion, and
• the presence of a metabolic derangement regarding the utilisation of oxygen at the cellular 
level.
Supraventricular or ventricular dysrhythmias are relatively common in these patients due to 
the presence of disorganised cellular architecture, expanded interstitial matrix and myocardial 
scarring. They are the cause of incidence of sudden arrest in this group of cardiomyopathy.
4.2. Signs and symptoms
The clinical presentation of HCM varies widely. These patients can present early in their life 
with debilitating symptoms or can live for decades asymptomatically while some others die 
suddenly. The most frequent symptoms include dyspnea, dizziness, exercise intolerance, 
angina, syncope, and/or sudden death.
Physical examination may be normal at rest but may reveal a double apical impulse, gallop 
rhythm, a systolic murmur and thrill in the presence of functional LVOTO. It is rare, but some 
people with hypertrophic cardiomyopathy can suffer sudden cardiac arrest during a vigorous 
physical workout. The physical activity can trigger dangerous arrhythmias leading to sudden 
death.
The major risk factors for sudden cardiac death are:
• a family history of sudden death;
• unexplained syncope;
• extreme hypertrophy of the left ventricular wall (0.30 mm);
• non-sustained ventricular tachycardia (VT)
Electrocardiography (ECG) changes include left atrial (LA) enlargement, pathologic Q waves, 
high QRS voltage complexes, ST segment depression, and inverted T waves in at least two or 
more consecutive leads.
Echocardiography can easily demonstrate the presence of myocardial hypertrophy. Ejection 
fraction is usually >80%, reflecting the increase in force of contraction of the heart. Echocardio-
graphy can also assess the mitral valvular apparatus, the presence of mitral regurgitation, and the 
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presence of LVOTO by demonstrating turbulent flow across the aortic valve. Pressure gradients 
across the LVOT can be measured. Echocardiography is useful in evaluating diastolic function 
of the heart.
Invasive measures like cardiac catheterisation allow direct measurement of the increased left 
ventricular end-diastolic pressure and the pressure gradient between the left ventricle and 
the aorta.
The definitive diagnosis of HCM can be made by an endomyocardial biopsy and DNA analy-
sis, but these diagnostic modalities are usually reserved for patients in whom the diagnosis 
cannot be established by non-invasive means.
4.3. Treatment
The varied clinical profile of HCM makes it difficult to establish some precise guidelines for 
the treatment of this condition. The treatment plan should be titrated according to individual 
patient requirements. However, it is prudent to mention that the patients who are at high risk 
for sudden death should receive aggressive treatment.
Medical management: Pharmacotherapy is aimed at reducing LVOTO, improving dia-
stolic filling, and possibly decreasing myocardial ischaemia. A variety of medical therapies 
have been used in these patients with the aim of altering the natural history. These include 
β-blockers, Ca2+ channel antagonists (verapamil or diltiazem), and disopyramide regimens, 
all of which seem to be effective as compared to no treatment in HCM patients. Most of these 
drugs used help HCM patients to improve their symptoms by reducing or eliminating the 
LVOT pressure gradient. These medications also reduce LVOTO during exercise by blunting 
the sympathetic response and are thus useful in treating the symptoms and attenuating the 
risk of sudden cardiac arrest. Atrial fibrillation often develops in these patients. It is associated 
with an increased risk of thromboembolism and congestive heart failure. Amiodarone is the 
most effective drug for prevention of repeated episodes of atrial fibrillation in these patients. 
Long-term anticoagulation is indicated in the patients with recurrent or chronic atrial fibril-
lation to prevent thromboembolic episode reducing the mortality and morbidity associated 
with it.
More recently, perhexiline, which augments myocyte energy supply, has been shown to 
improve diastolic dysfunction and symptomatology, but detailed studies are yet to follow.
Alcohol septal ablation [5]: Ethanol can be infused into the septal branches of the left anterior 
descending coronary artery and induce a targeted septal myocardial infarction (MI). Alcohol 
septal ablation is associated with some serious hazards, most common being the right bundle 
branch block, which has a post-procedural incidence of approximately 50%. Other complica-
tions include remote MI due to collateral circulation or an ethanol injection into the incorrect 
coronary, coronary dissection, ventricular septal rupture, heart failure, and heart block.
Surgical management: The American and European Colleges of Cardiology recommend 
myectomy in patients with:
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1. labile obstruction and peak LVOT pressure gradients ≥50 mm Hg during exercise or provo-
cation and resting gradients >30 mm Hg and.
2. NYHA class II through IV symptoms refractory to medical therapy.
Some patients may be candidates for implantable cardioverter-defibrillator (ICD) implanta-
tion while as principal surgical option is surgical myomectomy.
Prognosis: The overall mortality rate of HCM is 1% per annum. However, some patients at 
higher risk of sudden death as described before have an annual mortality rate of 5%.
Patients undergoing non-cardiac surgery: Most of the time, the patients with HCM are 
asymptomatic when they show up in the PAC clinic for elective surgeries. In the absence of 
signs and symptoms, the ECG findings may suggest that the patient has underlying HCM.
Initial patient evaluation should be aimed at determining the disease severity by assessing 
functional status of the patient, personal and family cardiac history, the presence or absence 
of cardiac and respiratory symptoms, history of rhythm disturbances, current medications, 
and previous strokes, or congestive heart failure history. During physical examination, all 
murmurs should be evaluated for dynamic changes with rest and exertion, and patients with 
murmurs that do not fulfil the criteria of a benign murmur should undergo an echocardio-
graphic examination before surgery. Patients should be instructed to continue their rate con-
trolling medications and maintain proper hydration preoperatively. Moreover, the presence 
of an automatic ICD and if it has been recently checked should be determined.
Preoperative management: A lot of patients with HCM may experience perioperative cardiac 
events like MI, congestive heart failure, severe hypotension, and supraventricular and ven-
tricular tachydysrhythmias. Therefore, we need to focus on understanding the basic patho-
physiology of the events and adjust our anaesthetic plans according to the patient needs.
In patients with HCM, preoperative administration of anti-anxiety medications may help to 
reduce anxiety and prevent the activation of anxiety-induced sympathetic response. Adequate 
preoperative intravenous fluid administration may help in preventing LVOTO and minimise 
the effect of positive pressure ventilation on central blood volume.
For patients who have an ICD in situ, the device should be turned off just before the surgery 
and an external defibrillator should be readily available and the ICD should be positively 
reactivated in the recovery room.
The anaesthetic goals are [4]:
• maintenance of sinus rhythm;
• reduction in sympathetic activity to reduce chronotropy and inotropy;
• the maintenance of systemic vascular resistance;
• maintenance of left ventricular filling.
Current Perspectives on Cardiomyopathies
http://dx.doi.org/10.5772/intechopen.79529
115
Tachycardia, arrythmias, and decreases in afterload will exacerbate LVOTO and may cause 
haemodynamic deterioration. In addition to this, increases in contractility (chronotropy) and 
decreases in preload will accentuate LVOTO. Therefore, the principle of treatment for hypo-
tension is volume expansion (including increasing preload in the Trendelenburg position) 
and use of drugs that increase systemic vascular resistance without a positive inotropic or 
chronotropic response (e.g. phenylephrine and vasopressin). Sympathetic response second-
ary to patient anxiety, intubation process, and surgical site incision and acute changes in 
preload, afterload, and contractility secondary to the pharmacological effects of anaesthetic 
agents, blood loss during surgery, and postoperative pain can precipitate haemodynamic col-
lapse. DC cardioversion may be necessary in case of sudden onset of atrial fibrillation that is 
haemodynamically unstable.
Although both general and neuraxial anaesthesia can be used, it is important to have a clear 
understanding of the haemodynamic changes associated with each option. Depending on 
the route of the anaesthetic drugs chosen, close monitoring and titration of the medications 
affecting heart rate, preload, afterload, contractility of myocardium, and sympathetic activity 
are important. Neuraxial techniques may also be considered. In general, a slow controlled 
titration of medication via an epidural is preferred over a single dose spinal anaesthesia with 
the aim of maintaining preload and afterload and avoiding sympathetic stimulation. Regional 
anaesthesia can be an invaluable tool to manage postoperative pain and in turn prevent the 
activation of sympathetic response in these patients.
In addition to the standard American Society of Anaesthesiologists monitoring requirements, 
an intra-arterial catheter and/or non-invasive pulse plethysmographic variability (PPV) index 
monitor and central venous pressure (CVP) monitoring may be considered. The overall hae-
modynamic goals include maintaining the mean arterial blood pressure at >65–70 mm Hg 
to maintain coronary perfusion pressure to the subendocardium in the hypertrophied heart. 
The most useful monitoring tool for patients undergoing high-risk surgery is TEE. TEE can 
determine whether haemodynamic alterations are caused by hypovolemia, increased LVOTO 
or SAM, or LV systolic dysfunction.
Postoperative management: Patient with HCM should be continuously monitored in the 
postoperative room. All factors that activate a sympathetic response like pain, hypothermia, 
shivering, anxiety, hypoxia, and hypercarbia should be immediately addressed. The mainte-
nance of euvolemia and prompt treatment of hypotension is very important.
5. Restrictive cardiomyopathy
Restrictive cardiomyopathy (RCM) is a disorder of the myocardium that occurs due to 
increased myocardial stiffness (decreased compliance) that leads to impaired ventricular 
filling. Size of both ventricle chambers and systolic function usually remains normal or 
near-normal until later stages of the disease. RCM may arise as a result of either inherited or 
acquired predispositions and diseases or a combination of the both, and can broadly be clas-
sified as infiltrative, non-infiltrative, storage disease, and endomyocardial fibrosis. Restrictive 
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cardiomyopathy is prevalent in tropical regions of the world, where incidence of endomyo-
cardial fibrosis is high. In non-tropical regions, idiopathic fibrosis is the common cause and is 
associated with increasing age. Other rare causes of RCM include amyloidosis, haemochro-
matosis, sarcoidosis, and eosinophilic endocarditis.
5.1. Pathophysiology
RCM is characterised by contracted stiff ventricles with progressive impairment of diastolic 
filling, leading to the haemodynamic problem of a low preload but high ventricular filling 
pressure. This pattern of diastolic dysfunction leads to dilation of the atria and elevation 
of mean atrial pressures, resulting in biventricular “backward heart failure” manifesting 
itself as pulmonary venous congestion leading to dyspnea as well as systemic venous pres-
sure elevation resulting in peripheral oedema. Systolic function is preserved in most cases. 
However, in spite of intact systolic function, the restrictive pathology on true ventricular 
preload limit the stroke volume, resulting in low cardiac output and ultimately hypoperfu-
sion of the tissues.
5.2. Signs and symptoms
RCM presents with signs and symptoms of both right and left heart failure. Patients complain 
of exercise intolerance because of diminished cardiac output. Patients often have a low vol-
ume pulse, an audible third heart sound, regurgitant murmurs, and a raised JVP with rapid X 
and Y descent that increases or fails to decrease on inspiration. Low blood pressures are often 
seen, complicating heart failure management. Pulmonary oedema is uncommon. Syncope 
occurs occasionally, often exertional, reflecting the limited ability of the heart to increase dia-
stolic filling and is an ominous sign. Syncope may also be aggravated by antihypertensive 
medications. Concomitant autonomic neuropathy can precipitate orthostatic hypotension as 
can volume contraction from nephrotic syndrome.
Arrhythmias and conduction disturbances are frequent. Less frequent cardiac manifestations 
include dynamic LV outflow obstruction, often confused with hypertrophic cardiomyopathy; 
cardiac ischaemia caused by amyloid deposition in intramural coronary arteries; and intracar-
diac thrombosis caused by atrial wall standstill, with a risk for systemic embolisation.
The ECG may demonstrate conduction abnormalities. The chest X-ray shows signs of pul-
monary congestion and/or pleural effusion, but cardiomegaly is absent. Echocardiography-
based two-dimensional and Doppler are essential for determining diastolic dysfunction and 
for distinguishing patients with RCM from patients with restrictive physiology because of 
constrictive pericarditis. Echocardiography may also provide information to suggest a spe-
cific diagnosis such as the presence of regional wall motion abnormalities in a non-coronary 
distribution and aneurysms, which would raise the suspicion for cardiac sarcoidosis (CS). 
Cardiac magnetic resonance (CMR) imaging can aid in the diagnostic process, but the use 
should be determined on an individual basis. Endomyocardial biopsy (EMB) may be helpful 
for establishing a diagnosis in some cases. Ultimately, diagnosis of any of the RCMs relies on 
a constellation of clinical, laboratory, and imaging findings.
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5.3. Management
Medical management: Treatment of RCM includes treating the underlying cause (if identi-
fied) and heart failure management. Diuretics are the mainstay of treatment to reduce volume 
overload. However, volume status in patients with RCM may be challenging to manage, as 
patients with RCM rely on high filling pressures to maintain cardiac output and excessive 
diuresis may result in tissue hypoperfusion. Digoxin must be used with great caution because 
it is potentially dysrhythmogenic in patients with amyloidosis. The use of β-blockers or cal-
cium channel blockers to increase filling time or to manage arrhythmias should be carefully 
introduced, as some patients may be intolerant. Angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blockers may also be considered, but the proof of benefit is lack-
ing, and these agents may not be well tolerated. Anticoagulation is required in patients with 
atrial fibrillation, mural thrombus, or evidence for systemic embolisation and may be helpful 
in most patients because of propensity for thrombus formation in the left atrial appendage.
Surgical management: No corrective surgery has yet been proposed that would be 100% 
effective in improving the heart function in RCM. Advanced heart failure therapies, including 
cardiac transplantation, may be beneficial for selected patients. Heart transplantation is the 
only effective surgery that can be offered to the patients with restrictive cardiomyopathy. It 
may be the best option for those who are already symptomatic at the time of diagnosis or in 
whom reactive pulmonary hypertension exists. Left ventricular assist device (LVAD) therapy 
may be particularly applicable in patients with RCM as a bridge to transplant or as definitive 
therapy.
5.4. Patients posted for non-cardiac surgery
RCM presents a huge challenge for anaesthetists due to the high risk of morbidity and mortal-
ity. General anaesthesia causes vasodilation, suppresses the myocardium, and reduces venous 
return. The latter can be worsened by intermittent positive pressure ventilation resulting in 
cardiac arrest. Invasive arterial blood pressure monitoring and transesophageal echocardiog-
raphy are useful in identifying the causes of cardiovascular instability [6].
The overall aims of anaesthesia are:
• sinus rhythm to be maintained if possible;
• to maintain adequate filling pressures;
• to maintain SVR in the presence of relatively fixed cardiac output.
• to manage electrolyte disturbances;
• to use anaesthetic agents with minimal cardiovascular effect like ketamine or etomidate.
6. Arrhythmogenic right ventricle cardiomyopathy
Arrhythmogenic right ventricle cardiomyopathy (ARVC) is characterised by structural abnor-
malities and cardiac dysfunction of mainly the right ventricle, but it can also involve the left 
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ventricle. It is a rare type of cardiomyopathy. It occurs if the muscle tissue in the right ven-
tricle dies and is replaced by a scar tissue. This disrupts the pathway of the heart’s electrical 
signals leading to arrhythmias.
ARVC usually affects teenagers or young adults. ARVC has a prevalence of 1 in 5000 among 
healthy young people. ARVC is seen in up to 20% of all causes of sudden death in young 
people. It is a complex genetic condition due to its genetic variation.
6.1. Pathophysiology
Histologically, the myocardial cells are replaced by the adipose and fibrous tissues. These 
alterations can form a re-entry electrical circuit triggering arrhythmias. ARVC usually starts 
as a localised disease with regional wall abnormalities. As the disease progresses, the right 
ventricle continues to lose the healthy tissue and dilates and becomes thin walled. Patients 
can develop right bundle branch block before they finally present with the symptoms of right 
ventricular failure between the fourth and fifth decades of life.
6.2. Signs and symptoms
Young patients often present with syncope, arrhythmia, cardiac arrest, or sudden death. The 
diagnosis of ARVC should be considered in:
• Young male athletes with cardiac symptoms.
• ECG showing ventricular tachycardia with left bundle branch block morphology.
• T-wave inversion in leads V1–V3.
• Premature ventricular complexes with left bundle branch block morphology.
• Spontaneous non-sustained ventricular tachycardia.
An accurate diagnosis of ARVC is important due to the high risk of drug-resistant arrhyth-
mias and sudden cardiac death. The diagnosis can be established by myocardial biopsy, 
which shows adipocytes and fibrous tissue. However, these changes can be localised and may 
not be present at the exact site of biopsy. The availability of cardiac MRI and the gadolinium 
enhancement techniques are now fundamental in diagnosing ARVC eliminating the need for 
biopsies.
6.3. Management
The main aim of medical management is to prevent or reduce the risk of fatal arrhythmias.
• Sotalol, verapamil, and amiodarone can be used.
• Due to the recurrence of arrhythmias and drug resistance, continuous Holter monitoring, 
or an electrophysiological study may be required. Catheter ablation can be used as a pal-
liative rather than a curative intervention. It is indicated in patients with monomorphic VT 
due to alocalised ARVC, with a drug-resistant arrhythmia, or with frequent intervention 
following ICD implantation [7].
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• Early placement of an ICD may be lifesaving.
• In some exceptional cases, heart transplantation may be required.
7. Peripartum cardiomyopathy
Peripartum cardiomyopathy is a rare, dilated form of cardiomyopathy of unknown cause that 
occurs during the peripartum period, that is, the third trimester of pregnancy until 5 months 
after delivery. Peripartum cardiomyopathy (PPCM) is a major concern for anaesthetists and 
can occur in 1 in 10,000 pregnancies, but it is higher in subsequent pregnancies [8]. Patients 
may present with severe heart failure during the third trimester or up to 5 months postpar-
tum. Many of these patients deliver via a normal vaginal delivery without complications; 
however, a few may require a Caesarean section.
Risk factors include maternal age > 30 years, multiparty, African descent, obesity, multiple 
pregnancy, hypertensive disorders, tocolytic therapy, viral infection, and cocaine use.
Diagnostic criteria of peripartum cardiomyopathy: The diagnosis of PPCM is usually made 
after the other causes of acute heart failure have been excluded. The criteria are:
• Heart failure developing towards the end of pregnancy or up to 5 months’ postpartum
• Absence of another identifiable cause of cardiac failure
• Absence of cardiac symptoms or disease before late pregnancy
• Left ventricular dysfunction - defined as an EF <45% or reduced fractional shortening of <30%
7.1. Signs and symptoms
The patients usually present with sign and symptoms of heart failure: dyspnea, fatigue, and 
peripheral oedema. In early stages, these signs may mimic the presenting features of normal 
late pregnancy.
Echocardiography may show new onset of unexplained LV dysfunction and documentation 
of a new finding of dilated cardiac chambers with LV systolic dysfunction during the period 
surrounding parturition.
7.2. Treatment
The main aim of treatment is to relieve the symptoms of heart failure. Diuretics, vasodilators, and 
digoxin can be used effectively. During pregnancy, vasodilation is accomplished with hydrala-
zine and nitrates. Intravenous immunoglobulin may have a beneficial effect. Thromboembolic 
complications are not uncommon, and anticoagulation may be required in most patients. Heart 
transplantation may be considered in patients who do not improve over time.
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7.3. Prognosis
The mortality in this group of patients is as high as 30–60% due to pulmonary oedema and 
systemic embolisation with most deaths occurring mostly within 3 months of delivery.
7.4. Anaesthetic management
We have a very little literature regarding the anaesthetic management of PPCM yet. 
Optimum fluid management and avoiding myocardial depression are the major concerns for 
anaesthetists.
According to a few case reports, both general anaesthesia and neuraxial blocks have been suc-
cessfully used for elective or emergency Caesarean section. Combined spinal epidural anaes-
thesia (CSE) is preferred by some. CSE causes less haemodynamic instability, has a higher 
success rate than epidural anaesthesia, results in better patient satisfaction, and provides 
good postoperative analgesia.
8. Takotsubo cardiomyopathy
Recently, Takotsubo cardiomyopathy has been described. Takotsubo cardiomyopathy is 
a rare condition of transient, reversible severe LV dysfunction and characterised by chest 
pain, dyspnoea, ST-T changes in ECG, ventricular arrhythmias, regional wall motion 
abnormalities on echocardiography, elevated cardiac enzymes, haemodynamic instability, 
pulmonary oedema, cardiogenic shock, or cardiac arrest without angiographic evidence 
of CAD.
8.1. Sign and symptoms
It is rare, usually occurs in postmenopausal women associated with stress and chest pain. 
ECG changes may include prolonged QTc interval which resolve in 1–2 days, ST-T changes, Q 
waves, resolve by discharge from hospital, and T inversion resolves slowly.
This condition is also known as apical ballooning syndrome and broken heart syndrome or 
stress-induced cardiomyopathy. Echocardiography shows akinesia of apical or midventricu-
lar segments leading to systolic dysfunction. The normal basal segments become hypercon-
tractile, giving a ballooned-out appearance of the apical or mid-cavity segments. Ballooning 
may lead to altered spatial relationships between mitral leaflets and subvalvular apparatus, 
which may result in MR and dynamic LVOTO causing SAM.
Reversible myocardial ischaemia is seen on myocardial perfusion imaging, and positron 
emission tomography and magnetic resonance imaging confirm LV dysfunction. Biopsy may 
show lymphocytic infiltrates. Plasma levels of brain natriuretic peptide, catecholamines, car-
diac enzymes and metanephrine are found to be elevated.
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8.2. Management
Optimal therapy is yet to be defined [9]. Beta blockers, diuretics, and ACE inhibitor and vaso-
dilators have been used. Adrenergic agonists and antiadrenergic therapy (beta adrenergic 
blockers or alpha 2 agonists) and QT prolonging medications are to be avoided.
8.3. Anaesthetic management
A principle anaesthetic goal is to avoid psychological and physical stress that could trig-
ger acute cardiomyopathy in susceptible patients. Thorough patient counselling, effective 
premedication and preoperative beta blocker therapy before transfer to operating room are 
highly effective.
Laryngoscopy, intubation, extubation, emergence, and inadequate postoperative pain control 
may cause a sympathetic response and increase catecholamine levels, so an optimal anaes-
thesia/analgesia is required in these phases. It is suggested that regional anaesthesia may be 
beneficial, but adequate studies to support this theory are not available.
It is unclear whether administration of inotropic drugs to treat systolic dysfunction is harm-
ful. Inotrope of choice remains unclear, though Milrinone, aphosphodiesterase inhibitor, and 
a calcium sensitizer, levosimendan are suggested. Mechanical support of circulation with 
IABP or LVAD is an option to tide over periods of crisis. Beta blocker therapy may not be hae-
modynamically tolerated or could be potentially hazardous. Beta agonists should be avoided 
or used carefully, vasopressors may be used and supportive treatment for CHF should be 
instituted. LV dysfunction resolves within 2–4 weeks. Most cases recover spontaneously with 
a mortality risk of 0–8%.Recurrence occurs in 2–5% cases [10].
9. Intensive care unit management
When a person is admitted with a diagnosis of cardiomyopathy, the main aims of therapy 
whether in the intensive care or coronary care unit are, to reduce the workload of the heart 
and to improve the pumping ability of the heart. This can be achieved with the help of drugs 
such as inotropes, diuretics, ACE inhibitors, beta blockers, calcium channel blockers, and so 
on, which aids in improving the pumping action of the heart muscle and treatment to ensure 
the proper volume of blood in the body.
Treatment of the patients in the intensive care unit depends not only on the type and the 
severity of cardiomyopathy but also condition of patient. Treatment may include conserva-
tive management with drugs, implantation of pacemakers, defibrillators for those prone to 
fatal heart rhythms, ventricular assist devices or extracorporeal membrane oxygenators for 
severe heart failure, or ablation for recurring dysrhythmias that cannot be managed by drugs 
or cardioversion. The goal of management in the intensive care unit is often symptomatic, and 
some patients may eventually require a heart transplant.
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10. Conclusion
Nowadays, cardiomyopathies are being identified increasingly as a result of improved means 
of detection with echocardiographic examination and an increase in the ageing population 
group. In addition, the presentation of this disease is varied. It may be sudden or already well 
known to the patient. Anaesthesia administration for patients with cardiomyopathy can lead 
to perioperative morbidity and mortality during elective or, more importantly in emergency 
surgeries. Therefore, anaesthesia and postoperative care have to be carefully titrated, planned, 
and monitored for every patient, for which we need a thorough understanding of the patho-
physiology of cardiomyopathies. The best approach would be a multidisciplinary team that 
includes anaesthetists, cardiologists, and surgeons. As anaesthesiologists, we have to expand 
our horizon from operating room to ICU with a thorough understanding of non-invasive and 
invasive monitoring methods and a basic knowledge of transthoracic echocardiography.
Abbreviations
AHA American Heart Association
ARSA American Society of Regional Anaesthesia
ARVC arrhythmogenic right ventricular cardiomyopathy
AS aortic stenosis
CAD coronary artery disease
CHF congestive heart failure
CMR cardiac magnetic resonance
CO cardiac output
CTR-D cardiac resynchronisation therapy device
CVP central venous pressure
DCM dilated cardiomyopathy
EF ejection fraction
EMB endomyocardial biopsy
HCM hypertrophic cardiomyopathy
IABP intra-arterial blood pressure
ICD implantable cardioverter-defibrillator
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LA left atrium
LV left ventricle
LVAD left ventricular assist device.
LVEDP left ventricular end-diastolic pressure
LVEF left ventricular ejection fraction
LVOTO left ventricular outflow tract obstruction
NYHA New York Heart Association
PPCM peripartum cardiomyopathy
PPV pulse plethysmographic variability
PVC premature ventricular complex
RCM restrictive cardiomyopathy
SAM systolic anterior moment
ScVO
2
 central venous oxygen saturation
SVR systemic vascular resistance
TEE trans esophageal echocardiography
VT ventricular tachycardia
WHO World Health Organisation
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